

# **Bone Marrow Transplantation**

Dr Lallindra Gooneratne

*Senior Lecturer, Department of Pathology and Honorary Consultant Haematologist, Faculty of Medicine, University of Colombo, and Director, Clinical Haematology and Bone Marrow Transplant Unit at Asiri Central Hospital, Colombo, Sri Lanka*

Haematopoietic stem cell transplantation (HSCT) is the only recognized curative option for many inherited and acquired haematological and immunological disorders. It is the standard of care for haematological malignancies such as myeloma, and relapsed/refractory leukaemias and lymphomas. HSCT can be autologous or allogeneic. An autologous HSCT is when a patient's own stem cells are mobilized following a remission achieved with chemotherapy, and infused back into the patient after high doses of chemotherapy referred to as conditioning. Allogeneic HSCT is when a compatible healthy donor's stem cells are infused into a patient following conditioning. The first successful allogeneic HSCT performed in Sri Lanka was in 2014. This lecture is a brief overview of HSCTs performed in Sri Lanka for both inherited and malignant diseases.